Katrin Soldau
Research Subjects
Research Interests
Katrin Soldau has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro M. Sevillano
Department of Pathology, UCSD, La Jolla, California, USA
2 shared publications - Christina J. Sigurdson
Department of Pathology, University of California at San Diego, La Jolla, CA 92093, USA
2 shared publications - Alexandra C. Newton
Department of Pharmacology, University of California at San Diego, La Jolla, CA 92037, USA
1 shared publication - Biswa Choudhury
Glycobiology Research and Training Center, UCSD, La Jolla, California, USA
1 shared publication - Brent D. Aulston
Department of Pathology, UCSD, La Jolla, California, USA
1 shared publication - Byron Caughey
TSE/Prion Biochemistry Section, DIR, National Institute of Allergy and Infectious Diseases (NIAID), Hamilton, MT, 59840, USA
1 shared publication
Latest Publications
- Open Access
- 4 April 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (10)
Mutant prion protein enhances NMDA receptor activity, activates PKC, and triggers rapid excitotoxicity in mice
Neuronal hyperexcitability precedes synapse loss in certain neurodegenerative diseases, yet the synaptic membrane interactions and downstream signaling events remain unclear. The disordered amino terminus of the prion protein (PrP C ) has been implicated in aberrant signaling in prion and Alzheimer’s disease. To disrupt neuronal interactions and signaling linked to the amino terminus, we CRISPR-engineered a knockin mouse expressing mutant PrP C (G92N), generating an N -linked glycosylation site between 2 functional motifs. Mice developed seizures and necrosis of hippocampal pyramidal neurons, similar to prion-infected mice and consistent with excitotoxicity. Phosphoproteomics analysis revealed phosphorylated glutamate receptors and calcium-sensitive kinases, including protein kinase C (PKC). Additionally, 92N-PrP C -expressing neurons showed persistent calcium influx as well as dendritic beading, which was rescued by an N -methyl-d-aspartate receptor (NMDAR) antagonist. Finally, survival of Prnp 92N mice was prolonged by blocking active NMDAR channels. We propose that dysregulated PrP C -NMDAR–induced signaling can trigger an excitatory-inhibitory imbalance, spongiform degeneration, and neurotoxicity and that calcium dysregulation is central to PrP C -linked neurodegeneration.
- 4 April 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (10)
Open AccessMutant prion protein enhances NMDA receptor activity, activates PKC, and triggers rapid excitotoxicity in mice
Neuronal hyperexcitability precedes synapse loss in certain neurodegenerative diseases, yet the synaptic membrane interactions and downstream signaling events remain unclear. The disordered amino terminus of the prion protein (PrP C ) has been implicated in aberrant signaling in prion and Alzheimer’s disease. To disrupt neuronal interactions and signaling linked to the amino terminus, we CRISPR-engineered a knockin mouse expressing mutant PrP C (G92N), generating an N -linked glycosylation site between 2 functional motifs. Mice developed seizures and necrosis of hippocampal pyramidal neurons, similar to prion-infected mice and consistent with excitotoxicity. Phosphoproteomics analysis revealed phosphorylated glutamate receptors and calcium-sensitive kinases, including protein kinase C (PKC). Additionally, 92N-PrP C -expressing neurons showed persistent calcium influx as well as dendritic beading, which was rescued by an N -methyl-d-aspartate receptor (NMDAR) antagonist. Finally, survival of Prnp 92N mice was prolonged by blocking active NMDAR channels. We propose that dysregulated PrP C -NMDAR–induced signaling can trigger an excitatory-inhibitory imbalance, spongiform degeneration, and neurotoxicity and that calcium dysregulation is central to PrP C -linked neurodegeneration.
- Open Access
- 2 March 2020
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (3) , 1350-1362
Prion protein glycans reduce intracerebral fibril formation and spongiosis in prion disease
Posttranslational modifications (PTMs) are common among proteins that aggregate in neurodegenerative disease, yet how PTMs impact the aggregate conformation and disease progression remains unclear. By engineering knockin mice expressing prion protein (PrP) lacking 2 N-linked glycans (Prnp180Q/196Q), we provide evidence that glycans reduce spongiform degeneration and hinder plaque formation in prion disease. Prnp180Q/196Q mice challenged with 2 subfibrillar, non–plaque-forming prion strains instead developed plaques highly enriched in ADAM10-cleaved PrP and heparan sulfate (HS). Intriguingly, a third strain composed of intact, glycophosphatidylinositol-anchored (GPI-anchored) PrP was relatively unchanged, forming diffuse, HS-deficient deposits in both the Prnp180Q/196Q and WT mice, underscoring the pivotal role of the GPI-anchor in driving the aggregate conformation and disease phenotype. Finally, knockin mice expressing triglycosylated PrP (Prnp187N) challenged with a plaque-forming prion strain showed a phenotype reversal, with a striking disease acceleration and switch from plaques to predominantly diffuse, subfibrillar deposits. Our findings suggest that the dominance of subfibrillar aggregates in prion disease is due to the replication of GPI-anchored prions, with fibrillar plaques forming from poorly glycosylated, GPI-anchorless prions that interact with extracellular HS. These studies provide insight into how PTMs impact PrP interactions with polyanionic cofactors, and highlight PTMs as a major force driving the prion disease phenotype.
- 2 March 2020
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (3) , 1350-1362
Open AccessPrion protein glycans reduce intracerebral fibril formation and spongiosis in prion disease
Posttranslational modifications (PTMs) are common among proteins that aggregate in neurodegenerative disease, yet how PTMs impact the aggregate conformation and disease progression remains unclear. By engineering knockin mice expressing prion protein (PrP) lacking 2 N-linked glycans (Prnp180Q/196Q), we provide evidence that glycans reduce spongiform degeneration and hinder plaque formation in prion disease. Prnp180Q/196Q mice challenged with 2 subfibrillar, non–plaque-forming prion strains instead developed plaques highly enriched in ADAM10-cleaved PrP and heparan sulfate (HS). Intriguingly, a third strain composed of intact, glycophosphatidylinositol-anchored (GPI-anchored) PrP was relatively unchanged, forming diffuse, HS-deficient deposits in both the Prnp180Q/196Q and WT mice, underscoring the pivotal role of the GPI-anchor in driving the aggregate conformation and disease phenotype. Finally, knockin mice expressing triglycosylated PrP (Prnp187N) challenged with a plaque-forming prion strain showed a phenotype reversal, with a striking disease acceleration and switch from plaques to predominantly diffuse, subfibrillar deposits. Our findings suggest that the dominance of subfibrillar aggregates in prion disease is due to the replication of GPI-anchored prions, with fibrillar plaques forming from poorly glycosylated, GPI-anchorless prions that interact with extracellular HS. These studies provide insight into how PTMs impact PrP interactions with polyanionic cofactors, and highlight PTMs as a major force driving the prion disease phenotype.